These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 2475266)
1. Immunoglobulin A and alpha 2-macroglobulin as tumor markers in bladder cancer. Khalifa A; Fathi O; Mousa MA; el Magraby H Chemioterapia; 1987 Jun; 6(2 Suppl):736-7. PubMed ID: 2475266 [No Abstract] [Full Text] [Related]
2. Editorial comment on: Serum proteomic profiling in patients with bladder cancer. Lotan Y Eur Urol; 2009 Dec; 56(6):996-7. PubMed ID: 19282102 [No Abstract] [Full Text] [Related]
3. [Clinical value of immunologic studies in patients with bladder tumors]. Romics I; Fehér J; Kisbenedek L; Horváth J; Balogh F Z Urol Nephrol; 1983; 76(2):79-85. PubMed ID: 6190325 [TBL] [Abstract][Full Text] [Related]
4. [Molecular markers of infiltrating cancer of the bladder]. Rigaud J; Tiguert R; Fradet Y Prog Urol; 2002 Nov; 12(5):1057-83. PubMed ID: 12536929 [No Abstract] [Full Text] [Related]
5. Contemporary non-imaging methods in diagnosis of bladder cancer: a review. De Graeve N; D'Hallewin MA; Baert L Acta Urol Belg; 1997 Mar; 65(1):55-8. PubMed ID: 9175284 [TBL] [Abstract][Full Text] [Related]
6. It's in your blood: spectral biomarker candidates for urinary bladder cancer from automated FTIR spectroscopy. Ollesch J; Heinze M; Heise HM; Behrens T; Brüning T; Gerwert K J Biophotonics; 2014 Apr; 7(3-4):210-21. PubMed ID: 24395618 [TBL] [Abstract][Full Text] [Related]
7. Granulocytic sarcoma of the urinary bladder. Hasegeli Uner A; Altundag K; Saglam A; Tekuzman G Am J Hematol; 2004 Apr; 75(4):262-3. PubMed ID: 15054826 [No Abstract] [Full Text] [Related]
8. Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. Schultz IJ; Witjes JA; Swinkels DW; de Kok JB Clin Chim Acta; 2006 Jun; 368(1-2):20-32. PubMed ID: 16480698 [TBL] [Abstract][Full Text] [Related]
9. The comparative evaluation of alpha-2-macroglobulin and immunoglobulin levels in sera of patients with bronchial asthma. Płusa T; Wasek Z; Kruszewski J Allerg Immunol (Leipz); 1983; 29(3):154-9. PubMed ID: 6195903 [TBL] [Abstract][Full Text] [Related]
10. [Clinical significance of alpha 1-macroglobulin analysis in biochemical laboratory tests]. Itoh Y Nihon Rinsho; 1989 Dec; 48 Suppl():176-8. PubMed ID: 2482905 [No Abstract] [Full Text] [Related]
11. Urine prothymosin-alpha as novel tumor marker for detection and follow-up of bladder cancer. Tzai TS; Tsai YS; Shiau AL; Wu CL; Shieh GS; Tsai HT Urology; 2006 Feb; 67(2):294-9. PubMed ID: 16461079 [TBL] [Abstract][Full Text] [Related]
12. Prostate specific antigen-alpha 2-macroglobulin complexes in prostate cancer patient sera. Heeb MJ; España F; Gittes RF; Griffin JH Biochem Mol Biol Int; 1995 Nov; 37(5):917-23. PubMed ID: 8624498 [TBL] [Abstract][Full Text] [Related]
13. Re: Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer. D. Margel, R. Tal and J. Baniel. J Urol 2007; 178: 2297-2301. Suzuki K J Urol; 2008 Jun; 179(6):2481; author reply 2481. PubMed ID: 18436255 [No Abstract] [Full Text] [Related]
14. [Alpha 1-antitrypsin, alpha 2-macroglobulin and reactive protein C in gastric cancer]. Dumitraşcu D; Radu D; Stanciu L; Ioniţă A; Petcovici M Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1989; 41(1):57-61. PubMed ID: 2479968 [TBL] [Abstract][Full Text] [Related]
15. [A case of transitional cell carcinoma of the urinary bladder with high serum level of CEA and CA19-9]. Inai H; Shimazui T; Yamamoto T; Yamauchi A; Uchida K; Takeshima H; Akaza H Hinyokika Kiyo; 2001 Aug; 47(8):583-6. PubMed ID: 11579601 [TBL] [Abstract][Full Text] [Related]
16. The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience. el-Ahmady O; Halim AB; el-Din AG Anticancer Res; 1999; 19(4A):2603-8. PubMed ID: 10470202 [TBL] [Abstract][Full Text] [Related]
18. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897 [TBL] [Abstract][Full Text] [Related]
19. Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer. van Poppel H; Billen J; Goethuys H; Elgamal AA; Gerits M; Mortelmans L; Blanckaert N; Baert L Anticancer Res; 1996; 16(4B):2205-7. PubMed ID: 8694544 [TBL] [Abstract][Full Text] [Related]
20. Plasma glutathione S-transferase pi 1-1 AND alpha 1-1 levels in patients with bladder cancer. Berendsen CL; Mulder TP; Peters WH J Urol; 2000 Dec; 164(6):2126-8. PubMed ID: 11061940 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]